#weight-loss-drugs

[ follow ]
fromFuturism
2 weeks ago

Doctors Are Warning That Ozempic's Severe Side Effects May Outweigh Its Benefits

GLP-1 weight loss drugs like Ozempic and Wegovy have concerning side effects, including potential vision impairment and increased risk of kidney problems.
#ozempic
US news
fromwww.npr.org
8 months ago

Drugmakers and pharmacists battle over who gets to make obesity drugs

Demand for Ozempic and its alternatives has led to compounded versions, but brand manufacturers are actively trying to eliminate this competition.
US news
fromwww.npr.org
8 months ago

Drugmakers and pharmacists battle over who gets to make obesity drugs

Demand for Ozempic and its alternatives has led to compounded versions, but brand manufacturers are actively trying to eliminate this competition.
fromBusiness Insider
3 weeks ago

The rise of Ozempic is a convenient excuse for retailers to cut back on plus-size options

It's difficult to envision a return to pre-pandemic levels of body positivity as brands continue to focus more on conventional beauty standards and thinness.
Fashion & style
#eli-lilly
fromwww.bbc.com
1 month ago

Weight loss jabs study begins after reports of pancreas issues

A study has been launched due to reports of serious side effects related to weight loss drugs potentially affecting the pancreas, prompting safety investigations.
Public health
fromNature
1 month ago

Obesity drugs show promise treating a new ailment: migraine

In a small study, the drug liraglutide reduced monthly migraine episodes by nearly half among people with obesity who experience the headache-inducing condition.
Alternative medicine
fromwww.theguardian.com
1 month ago

Weight loss drugs linked to higher risk of eye damage in diabetic patients

The study found that those who had been taking semaglutide or lixisenatide for at least six months had twice the risk of developing macular degeneration.
Alternative medicine
#novo-nordisk
Startup companies
fromFast Company
2 months ago

Novo Nordisk announces CEO transition as share price slips

Novo Nordisk's CEO Lars Fruergaard Jorgensen is stepping down amid market challenges despite leading the company through significant growth in the weight-loss drug sector.
Startup companies
fromFast Company
2 months ago

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

Novo Nordisk's market outlook improves with FDA's ban on GLP-1 drug copycats.
Despite profit forecasts lowering, investor sentiment towards Novo Nordisk remains optimistic.
Startup companies
fromFast Company
2 months ago

Novo Nordisk announces CEO transition as share price slips

Novo Nordisk's CEO Lars Fruergaard Jorgensen is stepping down amid market challenges despite leading the company through significant growth in the weight-loss drug sector.
Startup companies
fromFast Company
2 months ago

Novo Nordisk posts strong Q1 as weight-loss revolution claims another victim: WeightWatchers

Novo Nordisk's market outlook improves with FDA's ban on GLP-1 drug copycats.
Despite profit forecasts lowering, investor sentiment towards Novo Nordisk remains optimistic.
Alternative medicine
fromtime.com
2 months ago

Which Weight-Loss Drug Works the Best?

Zepbound shows superior weight loss compared to Wegovy in a recent clinical trial, influencing treatment decisions for obesity management.
Wearables
fromFuturism
2 months ago

Weight Watchers Goes Bankrupt After Rise of Ozempic-Like Drugs

Ozempic's popularity is reshaping the diet industry, severely affecting companies like Weight Watchers.
from24/7 Wall St.
2 months ago

Hims & Hers Shows It's More Than Just GLP-1 Drugs

Hims & Hers reported a remarkable 111% revenue increase to $586 million, driving its stock up 18%, alongside a 345% net income rise.
Growth hacking
fromwww.nytimes.com
3 months ago

Patients Cut Off From Cheaper Obesity Drugs as FDA Halts Sales of Copycats

FDA's crackdown on cheap weight-loss drugs threatens access for many Americans, raising treatment costs.
Compounded versions of Wegovy and Zepbound to be phased out as shortages are declared over.
#medicare
Medicine
fromtime.com
3 months ago

Medicare Will Not Cover GLP-1 Drugs for Weight Loss

Medicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.
Medicine
fromtime.com
3 months ago

Medicare Will Not Cover GLP-1 Drugs for Weight Loss

Medicare and Medicaid will not cover weight-loss drugs for obesity treatment, affecting millions.
OMG science
fromNature
3 months ago

Obesity-drug pioneers and 13,508 physicists win US$3-million Breakthrough Prizes

The scientists behind GLP-1 based weight-loss drugs Ozempic and Wegovy received a $3 million Breakthrough Prize for their life-saving contributions.
Wearables
fromwww.nytimes.com
4 months ago

How Much Should Weight Loss Drugs Like Wegovy and Zepbound Cost?

The cost of weight loss drugs Wegovy and Zepbound outweighs their health benefits, as per a study from the University of Chicago.
#health
Everyday cooking
fromwww.independent.ie
4 months ago

Eilis O'Hanlon on The Skinny Jab Revolution: Is replacing the pleasure that food can bring with the joyless asceticism of drugs really the only solution?'

Kathryn Thomas's documentary critically examines the implications of weight-loss drugs, emphasizing the balance of convenience against long-term health effects.
UK news
fromIndependent
5 months ago

'In the States, they're injecting 12-year-olds. That isn't here yet, but it's on the way' - Kathryn Thomas on her weight-loss drugs documentary

Weight-loss drugs are easily obtainable, but caution is advised due to personal and ethical concerns.
Everyday cooking
fromwww.independent.ie
4 months ago

Eilis O'Hanlon on The Skinny Jab Revolution: Is replacing the pleasure that food can bring with the joyless asceticism of drugs really the only solution?'

Kathryn Thomas's documentary critically examines the implications of weight-loss drugs, emphasizing the balance of convenience against long-term health effects.
UK news
fromIndependent
5 months ago

'In the States, they're injecting 12-year-olds. That isn't here yet, but it's on the way' - Kathryn Thomas on her weight-loss drugs documentary

Weight-loss drugs are easily obtainable, but caution is advised due to personal and ethical concerns.
Healthcare
fromwww.mercurynews.com
5 months ago

Patients struggle with lack of consistent coverage for popular weight-loss drugs

Access to obesity treatments is hindered by inconsistent insurance coverage and high costs, making it difficult for many to maintain weight loss.
from24/7 Wall St.
5 months ago

HIMS Stock Craters - Is It a Buying Opportunity?

Hims & Hers Health is facing significant challenges after the FDA announced the end of a semaglutide shortage, which jeopardizes their compounding drug sales.
Growth hacking
US news
fromWashington Post
5 months ago

Weight-loss drugs aren't just slimming waists. They're shifting the economy.

Weight-loss drugs are reshaping consumer habits and spending patterns, leading to a potential economic impact of billions.
Healthier weight-loss with GLP-1 drugs could boost GDP significantly.
Healthcare
fromBusiness Insider
5 months ago

New weight-loss drugs like Mounjaro are hot right now. Eli Lilly's CEO explains why they're so expensive.

Weight-loss drugs are expensive due to the high development costs and the limited time to recoup investment before patents expire.
fromTNW | Ecosystems
6 months ago

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

Verdiva's CEO Khurem Farooq emphasized, "People living with obesity and its complications deserve better options at each stage of their treatment journey..." making a case for improved treatment alternatives.
Miscellaneous
#zepbound
US news
fromwww.npr.org
7 months ago

FDA approves weight loss drug Zepbound to treat obstructive sleep apnea

Zepbound is the first FDA-approved drug for treating sleep apnea linked to obesity.
The drug aids in weight loss, which alleviates sleep apnea symptoms effectively.
US news
fromwww.npr.org
7 months ago

FDA approves weight loss drug Zepbound to treat obstructive sleep apnea

Zepbound is the first FDA-approved drug for treating sleep apnea linked to obesity.
The drug aids in weight loss, which alleviates sleep apnea symptoms effectively.
Medicine
fromFast Company
7 months ago

Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms

CagriSema failed to meet weight loss expectations in trials, causing significant stock decline for Novo Nordisk.
Health
fromLos Angeles Times
7 months ago

Opinion: Weight-loss drugs are great, but real food still matters

Weight-loss drugs like Ozempic and Wegovy are a start, but solving obesity requires addressing underlying food system issues.
Digital life
fromwww.nytimes.com
7 months ago

Weight Loss Drugs Changed Their Lives. Then They Lost Coverage.

Blue Cross Blue Shield of Michigan has limited coverage for weight-loss drugs, impacting thousands who rely on them for health and well-being.
Miscellaneous
fromwww.mediaite.com
7 months ago

Elon's Right On This!' View Hosts Jump To Musk's Side To Blast RFK Jr. Over Ozempic Criticism

Hosts on The View surprisingly agreed with Elon Musk on health drug availability despite their typical opposition to his views.
Health
fromWashington Post
7 months ago

Could Ozempic treat addiction?

GLP-1 receptor agonists may reduce cravings not just for food but also for drugs and alcohol, aiding recovery from addiction.
fromtime.com
7 months ago

Which Weight-Loss Drug Is Better: Wegovy or Zepbound?

Zepbound leads to more weight loss than Wegovy in clinical trials.
fromwww.bbc.com
9 months ago

Weight loss injections: How do drugs like Wegovy and Mounjaro work?

Weight-loss drugs like Wegovy and Mounjaro may help tackle obesity while boosting the economy, but NHS services face overwhelming demand.
Accessibility to weight-loss treatments is constrained by NHS resource limitations and prerequisites for patients.
Clinical effectiveness of drugs suggests significant weight loss potential, stressing the importance of lifestyle changes alongside medication.
fromBusiness Insider
10 months ago

Insider Today: Austin's genius housing fix

"Sen. Bernie Sanders pointed out during Wednesday's hearing that Ozempic costs an average of $969 monthly in the US, compared to $59 in Germany. Wegovy averages $1,349 a month in the US, while in Germany, it's only $140."
Privacy professionals
[ Load more ]